Generics - Oncology


Current filters:


Popular Filters

51 to 75 of 89 results

ScinoPharm and Foresee Pharma set up JV for novel oncological peptide drugs


Taiwanese drugmaker ScinoPharm (TWSE: 1789) and Foresee Pharmaceuticals, a Delaware, USA-based spin-out…

Asia-PacificForesee PharmaceuticalsGenericsleuprolideOncologyPharmaceuticalProductionResearchScinoPharm

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib


The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

MSF update on Novartis versus India, Supreme Court case


Humanitarian health organization Medecins Sans Frontieres (MSF) says it continues to follow progress…


Survey reveals 98.9% of US physicians experienced cancer drug shortages in last 12 months


The Community Oncology Alliance (COA), a US non-profit organization, announced the results of a drug…

GenericsHealthcareNorth AmericaOncologyPharmaceuticalPricing

India's Cipla cuts prices of three cancer drugs


Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021


Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021


While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region


Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the…

GenericsGP PharmHikma PharmaceuticalsLicensingLutrateOncologyRest of the World

Another negative Indian patent ruling, this time for Pfizer's Sutent


In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

India's IPAB rejects Bayer's "stay petition" regarding Nexavar


Over the weekend, the Intellectual Property Appellate Board (IPAB) of Chennai, India, has dismissed the…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer attempts to block generic Nexavar in India again slammed by MSF


German drug major Bayer (BAYN: DE) yesterday headed to India's Intellectual Property Appellate Board…


Indian hearings on Bayer Nexavar compulsory license delayed


India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Hospira re-launches generic Eloxatin in USA


US injectable drugs and infusion specialist Hospira (NYSE: HSP) last week announced the US re-launch…

GenericsMarkets & MarketingNorth AmericaOncology

Taiwan's ScinoPharm invests NT$1.1 billion in cytotoxic injectables facility


Taiwan based active pharmaceutical ingredients maker ScinoPharm (TWSE: 1789) says it plans to invest…

Asia-PacificFinancialGenericsMarkets & MarketingOncologyScinoPharm

51 to 75 of 89 results

Back to top